Advertising to Drive MannKind (MNKD) Afrezza Awareness and Adoption in Q3, Jefferies Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
MannKind (MNKD) Gains Amid Ongoing Talk of Short Squeeze
June 8, 2015 9:51 AM EDTMannKind (NASDAQ: MNKD) advanced over 5% Monday, extending recent gains amid ongoing talk of a squeeze in the heavily shorted name.
113 million shares of the stock were held short as of May 15, or about 42% of the float. Days to cover was 14.5 on average volume of 7.8 million.
... MoreMannKind (MNKD) Ticks Higher Despite Reports Affreza Difficult to Obtain
June 3, 2015 1:42 PM EDTMannKind (NASDAQ: MNKD) shares gained Wednesday, rising over 5%. Earlier its inhaled insulin drug Afrezza was featured in an article in the LA Times that discussed difficulties diabetes are having getting the drug due to doctor reluctance to prescribe it, as well as issues... More
